CCL13

CCL13 Full Name

chemokine (C-C motif) ligand 13

CCL13 Introduction

CCL13, also known as monocyte chemoattractant protein-4 (MCP-4), is a CC chemokine that has gained increasing attention in immunology, inflammation research, and precision medicine because of its central role in immune cell trafficking. Researchers studying chronic inflammatory diseases often face the challenge of identifying upstream mediators that connect immune activation with tissue damage, and CCL13 has emerged as one of these critical signaling molecules. By binding primarily to chemokine receptors CCR2 and CCR3, CCL13 regulates the migration of monocytes, eosinophils, basophils, and certain T-cell populations into inflamed tissues. This chemotactic activity makes CCL13 highly relevant in conditions characterized by persistent immune infiltration and cytokine imbalance. Recent studies between 2020 and 2025 have strengthened the understanding that CCL13 is not merely a secondary inflammatory marker, but an active participant in disease progression, immune remodeling, and microenvironment regulation across multiple organ systems.

The biological functions of CCL13 are particularly important in allergic inflammation, respiratory disease, and tissue repair. Elevated CCL13 expression has been repeatedly associated with asthma, chronic obstructive pulmonary disease (COPD), eosinophilic pneumonia, allergic rhinitis, chronic rhinosinusitis with nasal polyps, and atopic dermatitis, where it contributes to eosinophil recruitment and prolonged inflammatory signaling. For clinicians and researchers working on difficult-to-treat inflammatory disorders, CCL13 represents a promising biomarker candidate because its expression often correlates with disease severity and immune-cell infiltration. Beyond respiratory and skin diseases, CCL13 is increasingly linked to rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, obesity-associated inflammation, periodontal disease, and kidney injury. Interestingly, emerging evidence also suggests that CCL13 participates in wound healing and tissue regeneration, highlighting its dual role as both a pathogenic mediator and a regulator of repair processes depending on the biological context. This complexity has made CCL13 an attractive target for next-generation anti-inflammatory therapeutics and immune-modulating strategies.

In oncology and translational medicine, CCL13 has become especially relevant because chemokine-driven signaling strongly influences tumor immunity, macrophage recruitment, angiogenesis, and metastatic behavior. Recent breast cancer studies reported significant differences in CCL13 expression between malignant and benign tissues, with aggressive tumors showing associations between altered CCL13 levels and proliferative markers such as Ki67. Although some tumor datasets demonstrate lower overall CCL13 expression in cancer tissues compared with normal adjacent tissues, its functional impact within the tumor microenvironment may still contribute to immune-cell reshaping and cancer progression through CCR2/CCR3-mediated pathways. Researchers are also investigating how hypoxia, a hallmark of solid tumors, indirectly affects CCL13-related signaling by enhancing CCR2 expression in macrophages. Beyond cancer, abnormal CCL13 activity has been linked to neurological disorders, multiple sclerosis, psychiatric conditions, HIV infection, and autoimmune diseases, emphasizing its broad clinical importance. As precision immunology and targeted cytokine therapies continue to evolve, CCL13 is increasingly recognized as a valuable molecular target for understanding chronic inflammation, immune dysregulation, and disease heterogeneity across diverse patient populations.

Alternate Names for CCL13

CCL13; chemokine (C-C motif) ligand 13; NCC1; CKb10; MCP-4; NCC-1; SCYL1; SCYA13; C-C motif chemokine 13; CK-beta-10; new CC chemokine 1; small-inducible cytokine A13; monocyte chemotactic protein 4; monocyte chemoattractant protein 4; small inducible cytokine subfamily A (Cys-Cys), member 13;

• 1.Li L, et al.; CCL13 and human diseases. Front Immunol. 2023, 14:1176639.
  2.Korbecki J, et al.; CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020, 21(21):8412.